[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tectonic Therapeutic Inc (TECX)

Tectonic Therapeutic Inc (TECX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 605,129
  • Shares Outstanding, K 18,869
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,150 K
  • EBIT $ -93 M
  • EBITDA $ -92 M
  • 60-Month Beta 3.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.51

Options Overview Details

View History
  • Implied Volatility 121.07% (+2.67%)
  • Historical Volatility 66.96%
  • IV Percentile 56%
  • IV Rank 34.03%
  • IV High 213.83% on 10/07/25
  • IV Low 73.23% on 08/18/25
  • Expected Move (DTE 31) 6.16 (19.22%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 150
  • Volume Avg (30-Day) 299
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 6,263
  • Open Int (30-Day) 2,983
  • Expected Range 25.91 to 38.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.40
  • Number of Estimates 4
  • High Estimate $-1.33
  • Low Estimate $-1.47
  • Prior Year $-1.07
  • Growth Rate Est. (year over year) -30.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.54 +8.55%
on 06/23/26
39.53 -18.87%
on 07/06/26
+2.05 (+6.83%)
since 06/18/26
3-Month
26.31 +21.89%
on 05/07/26
39.53 -18.87%
on 07/06/26
+3.31 (+11.51%)
since 04/20/26
52-Week
14.39 +122.94%
on 09/25/25
39.53 -18.87%
on 07/06/26
+10.16 (+46.37%)
since 07/18/25

Most Recent Stories

More News
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 TX2100 advanced into Phase 1a healthy volunteer clinical trial...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic to Participate in March Investor Conferences

WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 32.07 (-1.63%)
MRNA : 59.49 (-3.77%)
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc . (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic to Participate in December Investor Conferences

WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights

Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure...

TECX : 32.07 (-1.63%)
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated...

TECX : 32.07 (-1.63%)

Business Summary

Tectonic Therapeutic Inc. is a biotechnology company developing GPCR -targeted therapeutic proteins. Tectonic Therapeutic Inc., formerly known as AVROBIO Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 35.21
2nd Resistance Point 34.30
1st Resistance Point 33.19
Last Price 32.07
1st Support Level 31.17
2nd Support Level 30.26
3rd Support Level 29.15

See More

52-Week High 39.53
Last Price 32.07
Fibonacci 61.8% 29.92
Fibonacci 50% 26.96
Fibonacci 38.2% 23.99
52-Week Low 14.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.